September 6, 2012
Takeda Pharmaceutical and NPS Pharmaceuticals (headquartered in New Jersey, US) announced on September 5 that its subsidiary Nycomed Denmark ApS obtained a European market authorization from the European Commission (EC) for the short bowel syndrome (SBS) treatment Revestive (teduglutide). In...read more